Literature DB >> 16102439

Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients.

Ingrid M Seipelt1, Elfriede Pahl, Ralf G Seipelt, Constantine Mavroudis, Carl L Backer, Veronica Stellmach, Mona Cornwell, Susan E Crawford.   

Abstract

BACKGROUND: Chronic inflammation and angiogenesis have been implicated in the pathogenesis of both cardiac allograft vasculopathy (CAV) and age-related vasculopathy. Because concurrent atherosclerosis does not complicate assessment of CAV in children, we sought to characterize the spectrum of coronary lesions in this population and determine whether inflammatory infiltrates and angiogenesis correlate with severity of CAV.
METHODS: In 18 pediatric heart specimens CAV was graded 1 to 4 (none to severe). Each case was assigned to either: Group I, no inflammation; Group II, perivascular inflammation; or Group III, perivascular and neointimal inflammation. Inflammatory infiltrates were immunophenotyped using anti-CD3, anti-CD20 and HAM 56. Angiogenesis was assessed by determining microvascular density (MVD) in 5 high-power fields (HPFs) per section.
RESULTS: CAV was evident in 94% of cases, and inflammation in 61%. Cases with neointimal inflammation had significantly more severe CAV compared with cases without inflammation (2.7 +/- 0.16 vs 1.9 +/- 0.2, p = 0.002). MVD was significantly higher in both inflammation groups (Groups II and III) compared with Group I (4.1 +/- 0.5 per HPF and 5.9 +/- 0.5 vs 3.1 +/- 0.7, p = 0.018 and p = 0.002) and correlated with the degree of CAV (p = 0.007). The perivascular infiltrates (Group II, n = 5) contained lymphocytes, macrophages and plasma cells, and 67% of neointimal infiltrates (Group III, n = 6) also contained eosinophils.
CONCLUSIONS: CAV in children is more common than previously reported. Our data indicate that CAV is often associated with inflammation and that adventitial angiogenesis correlated with the severity of CAV.

Entities:  

Mesh:

Year:  2005        PMID: 16102439     DOI: 10.1016/j.healun.2004.07.005

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Cardiac allograft vasculopathy: real or a normal morphologic variant?

Authors:  Stuart Houser; Ashok Muniappan; James Allan; David Sachs; Joren Madsen
Journal:  J Heart Lung Transplant       Date:  2007-02       Impact factor: 10.247

Review 2.  Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.

Authors:  Jordan S Pober; Dan Jane-wit; Lingfeng Qin; George Tellides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-05       Impact factor: 8.311

Review 3.  Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.

Authors:  Kristofor Glinton; Matthew DeBerge; Xin-Yi Yeap; Jenny Zhang; Joseph Forbess; Xunrong Luo; Edward B Thorp
Journal:  Semin Immunopathol       Date:  2018-08-23       Impact factor: 9.623

4.  Association of periarterial neovascularization with progression of cardiac allograft vasculopathy and long-term clinical outcomes in heart transplant recipients.

Authors:  Hideki Kitahara; Kozo Okada; Shigemitsu Tanaka; Hyoung-Mo Yang; Kojiro Miki; Yuhei Kobayashi; Takumi Kimura; Helen Luikart; Paul G Yock; Alan C Yeung; Peter J Fitzgerald; Kiran K Khush; William F Fearon; Yasuhiro Honda
Journal:  J Heart Lung Transplant       Date:  2016-03-10       Impact factor: 10.247

5.  Recombinant adenoviral gene transfer does not affect cardiac allograft vasculopathy.

Authors:  Vinay P Rao; Stefano E Branzoli; Davide Ricci; Naoto Miyagi; Timothy O'Brien; Henry D Tazelaar; Stephen J Russell; Christopher G A McGregor
Journal:  J Heart Lung Transplant       Date:  2007-12       Impact factor: 10.247

6.  Evaluation of coronary adventitial vasa vasorum using 3D optical coherence tomography--animal and human studies.

Authors:  Tatsuo Aoki; Martin Rodriguez-Porcel; Yoshiki Matsuo; Andrew Cassar; Teak-Geun Kwon; Federico Franchi; Rajiv Gulati; Sudhir S Kushwaha; Ryan J Lennon; Lilach O Lerman; Erik L Ritman; Amir Lerman
Journal:  Atherosclerosis       Date:  2015-01-20       Impact factor: 5.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.